RNA Expression-based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab

Conclusion Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC who were treated with regorafenib plus nivolumab might be of value for predictive clinical benefit. Further studies are needed to evaluate the predictive role of Xerna™ TME Panel analysis in patients with refractory metastatic pMMR CRC.PMID:38061339 | DOI:10.1159/000535599

Source: Oncology - December 7, 2023 Category: Cancer & Oncology Authors: Ruoyu Miao Dae Won Kim James Yu Mokenge Malafa Rutika Mehta Jonathan Strosberg Iman Imanirad Seema Iyer Mark Uhlik Laura Benjamin Richard Kim Source Type: research